Lipid Risk Factors in Vitiligo: Homocysteine the Connecting Link?

Taneja, Kanchan; Taneja, Jitendra; Kaur, Charanjeet; Patel, Seema M; Haldar, Deepa

doi:10.7754/clin.lab.2020.200120

Cited by 13 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that vitiligo and MetS share some common pathophysiological pathways, such as oxidative stress, hyper-homocysteine, and the elevation of proinflammatory cytokines (e.g., IL-6) [12,13]. A series of epidemiological studies have investigated the association of vitiligo with MetS or its components, however, the conclusion is inconsistent across these studies.…”

Section: Association Between Vitiligo and Relevant Components Of Meta...mentioning

confidence: 99%

Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta‐analysis

Kang

Zhang

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Background and objectives This study aimed to investigate the association of vitiligo with metabolic syndrome (MetS) and its relevant components. Material and methods We searched PubMed, Web of Science, Cochrane Library and Embase databases from inception to March 30, 2021, for relevant studies. Cross‐sectional and case‐control studies that reported either the prevalence or odds ratio [OR] of MetS or its components in vitiligo patients were included. Data were pooled using either random‐effects model or fixed‐effects model according to the heterogeneity. Results Thirty studies with a total of 28,325 vitiligo patients were included. Significant associations were found between vitiligo and diabetes mellitus (pooled OR, 3.30; 95 % confidence interval [CI], 2.10–5.17) and between vitiligo and obesity (pooled OR, 2.08; 95 % CI, 1.40–3.11). The overall prevalence of hypertension in the patients with vitiligo was 19.0 % (95 % CI, 2.0 %–36.0 %). Conclusions Our findings suggest the association of vitiligo with diabetes mellitus, obesity, and hypertension. It is recommended for dermatologists to take these associations into account so as to identify potential comorbidities promptly in vitiligo patients. Additionally, vitiligo patients are advised to monitor the indexes including BMI, blood glucose, and blood pressure levels and the consultation with specialists is necessary upon abnormal changes of these indexes.

show abstract

Section: Association Between Vitiligo and Relevant Components Of Meta...mentioning

confidence: 99%

Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta‐analysis

Kang

Zhang

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Current findings indicate a significant rise in lipid profile markers except for HDL-c levels in vitiligo patients compared to control subjects, similar to previous studies. [ 22 ] On the other hand, Rodriguez-Martin et al . [ 23 ] study showed that vitiligo patients had higher serum HDL-c levels and lower serum TG, which they attributed to higher levels of superoxide dismutase and glutathione peroxidase in patients with active vitiligo, and this enzymatic base could be the reason why vitiligo sufferers are less prone to dyslipidemia.…”

Section: Discussionmentioning

confidence: 99%

A notorious trio! Inflammation, metabolic syndrome and vitiligo

Mustafa,

Hamed,

Kadah

et al. 2023

Indian Dermatol Online J

View full text Add to dashboard Cite

Background: There is evidence to support that vitiligo is linked to metabolic syndrome (MS), confirming its systemic nature. However, the underlying pathogenic mechanisms remain unknown. Objectives: To reveal the possible association of MS with vitiligo. We also attempted to study the connection between some inflammatory markers and MS in vitiligo patients to evaluate their utility in predicting MS risk. Materials and Methods: The study included 100 vitiligo patients with an age range between 18 to 60 years and 100 controls with matched age, gender, and body mass index. All subjects were tested for MS components. Serum visceral adipose tissue-derived serine protease inhibitor (vaspin), fatty acid binding protein 4 (FABP4), vascular adhesion protein 1 (VAP-1), chitinase-3-like protein 1 (YKL-40), and high-sensitivity C-reactive protein (hs-CRP) were also measured. Results: Regarding MS, it was observed in 22.0% of vitiligo patients and 2.0% of control subjects ( P < 0.001). Serum FABP4, VAP-1, YKL-40, and hs-CRP concentrations were higher in patients than in the control group ( P < 0.05 each), and their levels showed high sensitivity and specificity to differentiate MS when using the receiver operating characteristic (ROC). Levels of these markers, except serum vaspin, were significantly positively correlated with lipid profile markers (except high-density lipoprotein cholesterol) and fasting blood glucose levels ( P < 0.05 each). Conclusion: MS was more common in vitiligo patients. The levels of the biomarkers studied were significantly higher in vitiligo patients. Furthermore, their levels accurately predicted MS in vitiligo patients. According to current research, these markers may be useful in assessing MS risk in vitiligo patients. Extensive research, however, is required.

show abstract

“…Taneja et al, in their study, found elevated levels of LDL cholesterol, reduced levels of HD -cholesterol, increased LDL-to-HDL ratio, and increased levels of homocysteine. They concluded that the result of their study might be due to ongoing abnormal metabolic processes, and homocysteine may be a precipitating factor [ 22 ]. Increased homocysteine levels were also found in studies by Tsai et al and Singh et al correlating to disease activity [ 23 , 24 ].…”

Section: Reviewmentioning

confidence: 99%

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

show abstract

Lipid Risk Factors in Vitiligo: Homocysteine the Connecting Link?

Cited by 13 publications

References 0 publications

Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta‐analysis

Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta‐analysis

A notorious trio! Inflammation, metabolic syndrome and vitiligo

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Contact Info

Product

Resources

About